Benjamin Edwards Inc
PRME icon

Benjamin Edwards Inc’s Prime Medicine PRME Stock Holding History

Benjamin Edwards Inc’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.1K Sell
10,329
-3,523
-25% -$11.7K ﹤0.01% 1417
2026
Q1 		$48.2K Buy
+13,852
New +$52.7K ﹤0.01% 1350
2025
Q2 		– Sell
-21,101
Closed -$42K – 1200
2025
Q1 		$42K Sell
21,101
-820
-4% -$2.09K ﹤0.01% 1072
2024
Q4 		$63.9K Sell
21,921
-1,275
-5% -$4.48K ﹤0.01% 1098
2024
Q3 		$89.6K Buy
23,196
+23,010
+12,371% +$107K ﹤0.01% 1076
2024
Q2 		$1K Sell
186
-121
-39% -$734 ﹤0.01% 696
2024
Q1 		$2K Sell
307
-7
-2% -$53 ﹤0.01% 694
2023
Q4 		$3K Sell
314
-7
-2% -$54 ﹤0.01% 618
2023
Q3 		$3K Hold
321
– – ﹤0.01% 614
2023
Q2 		$5K Buy
321
+139
+76% +$1.94K ﹤0.01% 610
2023
Q1 		$2K Buy
182
+35
+24% +$570 ﹤0.01% 667
2022
Q4 		$3K Buy
+147
New +$2.65K ﹤0.01% 663

Other funds holding PRME

Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Benjamin Edwards Inc's PRME Position: Q2 2026 in Review

Benjamin Edwards Inc reduced its Prime Medicine (PRME) stake by 25% in Q2 2026, selling an estimated $11.7K and leaving 10,329 shares worth $38.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1417.

Benjamin Edwards Inc first reported a position in PRME in Q4 2022 and has held it in 12 quarters since. The position peaked at $89.6K in Q3 2024. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Benjamin Edwards Inc held 10,329 shares of Prime Medicine worth $38.1K as of Q2 2026.
  • Benjamin Edwards Inc sold 3,523 Prime Medicine shares in Q2 2026, an estimated $11.7K.
  • Prime Medicine made up ﹤0.01% of Benjamin Edwards Inc's portfolio in Q2 2026, its #1417 holding.
  • Benjamin Edwards Inc first reported a position in Prime Medicine in Q4 2022 and has held it in 12 quarters since.
  • Benjamin Edwards Inc's Prime Medicine position peaked at $89.6K in Q3 2024.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Benjamin Edwards Inc's 13F filing for Q2 2026, filed 24 Jul 2026.